Caffeic acid phenethyl amide improves glucose homeostasis and attenuates the progression of vascular dysfunction in Streptozotocin-induced diabetic rats
Open Access
- 6 July 2013
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 99
Abstract
Background: Glucose intolerance and cardiovascular complications are major symptoms in patients with diabetes. Many therapies have proven beneficial in treating diabetes in animals by protecting the cardiovascular system and increasing glucose utilization. In this study, we evaluated the effects of caffeic acid phenethyl amide (CAPA) on glucose homeostasis and vascular function in streptozotocin (STZ)-induced type 1 diabetic rats. Methods: Diabetes (blood glucose levels > 350 mg/dL), was induced in Wistar rats by a single intravenous injection of 60 mg/kg STZ. Hypoglycemic effects were then assessed in normal and type 1 diabetic rats. In addition, coronary blood flow in Langendorff-perfused hearts was evaluated in the presence or absence of nitric oxide synthase (NOS) inhibitor. The thoracic aorta was used to measure vascular response to phenylephrine. Finally, the effect of chronic treatment of CAPA and insulin on coronary artery flow and vascular response to phenylephrine were analyzed in diabetic rats. Results: Oral administration of 0.1 mg/kg CAPA decreased plasma glucose in normal (32.9 ± 2.3% decrease, P < 0.05) and diabetic rats (11.8 ± 5.5% decrease, P < 0.05). In normal and diabetic rat hearts, 1–10 μM CAPA increased coronary flow rate, and this increase was abolished by 10 μM NOS inhibitor. In the thoracic aorta, the concentration/response curve of phenylephrine was right-shifted by administration of 100 μM CAPA. Coronary flow rate was reduced to 7.2 ± 0.2 mL/min at 8 weeks after STZ-induction. However, 4 weeks of treatment with CAPA (3 mg/kg, intraperitoneal, twice daily) started at 4 weeks after STZ induction increased flow rate to 11.2 ± 0.5 mL/min (P < 0.05). In addition, the contractile response induced by 1 μM phenylephrine increased from 6.8 ± 0.6 mN to 11.4 ± 0.4 mN (P < 0.05) and 14.9 ± 1.4 mN (P < 0.05) by insulin (1 IU/kg, intraperitoneal) or CAPA treatment, respectively. Conclusions: CAPA induced hypoglycemic activity, increased coronary blood flow and vascular response to phenylephrine in type 1 diabetic rats. The increase in coronary blood flow may result from endothelial NOS activation. However, the detailed cellular mechanisms need to be further evaluated.Keywords
This publication has 53 references indexed in Scilit:
- Acute and chronic animal models for the evaluation of anti-diabetic agentsCardiovascular Diabetology, 2012
- Caffeic Acid Phenylethyl Amide Protects against the Metabolic Consequences in Diabetes Mellitus Induced by Diet and StreptozocinEvidence-Based Complementary and Alternative Medicine, 2012
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2011
- Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic ratsCardiovascular Diabetology, 2011
- Molecular role of GATA binding protein 4 (GATA-4) in hyperglycemia-induced reduction of cardiac contractilityCardiovascular Diabetology, 2011
- Insulin Therapy for Type 2 DiabetesDiabetes Care, 2009
- IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK ratProceedings of the National Academy of Sciences, 2009
- Caffeic acid phenethyl ester inhibits invasion and expression of matrix metalloproteinase in SK-Hep1 human hepatocellular carcinoma cells by targeting nuclear factor kappa BGenes & Nutrition, 2007
- The Effect of Intensive Diabetes Treatment on Resting Heart Rate in Type 1 DiabetesDiabetes Care, 2007
- Serotonin enhances β-endorphin secretion to lower plasma glucose in streptozotocin-induced diabetic ratsLife Sciences, 2007